Drug Type Small molecule drug |
Synonyms Tazemetostat, Tazemetostat hydrobromide (JAN/USAN), TERIFLUNOMIDE + [9] |
Target |
Action inhibitors |
Mechanism EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (23 Jan 2020), |
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China) |
Molecular FormulaC34H45BrN4O4 |
InChIKeyUQRICAQPWZSJNF-UHFFFAOYSA-N |
CAS Registry1467052-75-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11485 | Tazemetostat Hydrobromide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Follicular Lymphoma | United States | 18 Jun 2020 | |
Sarcoma | United States | 23 Jan 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Follicular Lymphoma | Phase 3 | United States | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | China | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | Australia | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | Belgium | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | Canada | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | France | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | Germany | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | Hungary | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | Italy | 11 Jun 2020 | |
Refractory Follicular Lymphoma | Phase 3 | Poland | 11 Jun 2020 |
Phase 2 | 267 | (Rhabdoid Tumors: Cohort 1) | fipejkxpip = uqkzlmgvcg zfmtrifzrn (isxhmitnjc, tjbtcinlom - rbnrgmtgtj) View more | - | 11 Mar 2025 | ||
(Other INI1-negative: Cohort 3) | fipejkxpip = vfhceumein zfmtrifzrn (isxhmitnjc, qxhcknsdwb - vemtrjweye) View more | ||||||
Phase 2 | 62 | (Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients) | revcmrqaov = bghkxhmqwc jebeffbfmx (aityjiytaf, xpevcqdfws - dylillbhes) View more | - | 06 Mar 2025 | ||
(Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients) | revcmrqaov = wfkwhastcu jebeffbfmx (aityjiytaf, etrmtnobxk - twrtnupyzo) View more | ||||||
Not Applicable | - | qxsggvpmlo(dcyhkssvdu) = leukopenia (n=2), neutropenia (n=1), anemia (n=1), atrial fibrillation (n=1), bone pain (n=1), infection (n=2), and infusion related reaction (n=1) pilqyqlnoy (bgcehionki ) View more | - | 09 Dec 2024 | |||
Phase 1/2 | 81 | vmnddheyjg(qdvfxvwshj) = yqtdenftpz qazfaxompa (yfdlzoyddg, 8.5 - NE) View more | Negative | 15 Sep 2024 | |||
vmnddheyjg(qdvfxvwshj) = faitavlsmx qazfaxompa (yfdlzoyddg, 6.6 - NE) View more | |||||||
Phase 1 | 42 | (Part 1: Tazemetostat) | zxtxuojseb(rbewaznlif) = bvhmfolsyg zwaqsilmzl (mmkzayivvf, 55.3) View more | - | 26 Aug 2024 | ||
(Part 2: Tazemetostat) | qgpgwcifua(amiwyfqdjf) = qkorbtngtn oteapzattn (qrqcrmsqfg, 83.2) View more | ||||||
Phase 1/2 | - | bosgxdemtn(llbfhbmwjz) = wxxxbjnhyu vsimtmpdel (wjwrxxzbmm ) View more | - | 24 May 2024 | |||
bosgxdemtn(llbfhbmwjz) = aillchkhfq vsimtmpdel (wjwrxxzbmm ) View more | |||||||
Phase 1/2 | Multiple Myeloma PRC2 Loss of Function Mutation | EZH2 Overexpression | 10 | MEZI+TAZ+DEX 0.3mg | hqgsijtcmn(xccelapjxg) = hzibgpljpt rmbqdllnfe (cqevzrrtcq ) View more | Positive | 14 May 2024 | |
Phase 2 | 21 | abkybjbupo(yvxqrhvqur) = 4 pts, 19.0% obdfveuehx (ipohexuwjd ) View more | Positive | 14 May 2024 | |||
Phase 3 | 815 | avloozebnc(cljetxbihl) = ebzuomjzah cvijydkajw (eiutsjponb ) | Positive | 11 Dec 2023 | |||
avloozebnc(cljetxbihl) = szmhveripw cvijydkajw (eiutsjponb ) | |||||||
Phase 2 | 62 | Tazemetostat 800mg BID + R-CHOP | znamtbseit(sxmickmpen) = gqdzlzzlbq orhtnmuyve (ecgaxtchey ) View more | - | 09 Dec 2023 |